[go: up one dir, main page]

NO20040353L - Ny terapeutsk metode - Google Patents

Ny terapeutsk metode

Info

Publication number
NO20040353L
NO20040353L NO20040353A NO20040353A NO20040353L NO 20040353 L NO20040353 L NO 20040353L NO 20040353 A NO20040353 A NO 20040353A NO 20040353 A NO20040353 A NO 20040353A NO 20040353 L NO20040353 L NO 20040353L
Authority
NO
Norway
Prior art keywords
therapeutic method
new therapeutic
new
therapeutic
Prior art date
Application number
NO20040353A
Other languages
English (en)
Norwegian (no)
Inventor
Richard Graham Knowles
Peter Ward
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20040353L publication Critical patent/NO20040353L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO20040353A 2001-07-27 2004-01-26 Ny terapeutsk metode NO20040353L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0118373.0A GB0118373D0 (en) 2001-07-27 2001-07-27 Novel therapeutic method
PCT/EP2002/008322 WO2003011274A2 (en) 2001-07-27 2002-07-25 Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma

Publications (1)

Publication Number Publication Date
NO20040353L true NO20040353L (no) 2004-03-26

Family

ID=9919332

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040353A NO20040353L (no) 2001-07-27 2004-01-26 Ny terapeutsk metode

Country Status (18)

Country Link
US (1) US20040180918A1 (es)
EP (1) EP1411914A2 (es)
JP (1) JP2004538302A (es)
KR (1) KR20040029384A (es)
CN (1) CN1551763A (es)
AR (1) AR034900A1 (es)
BR (1) BR0211450A (es)
CA (1) CA2455520A1 (es)
CO (1) CO5550426A2 (es)
GB (1) GB0118373D0 (es)
HU (1) HUP0401614A2 (es)
IL (1) IL160017A0 (es)
MX (1) MXPA04000793A (es)
NO (1) NO20040353L (es)
PL (1) PL368585A1 (es)
RU (1) RU2004105865A (es)
WO (1) WO2003011274A2 (es)
ZA (1) ZA200400410B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
DE10230769A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren
MXPA05010160A (es) * 2003-03-28 2005-11-16 Altana Pharma Ag Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias.
EP1610788A1 (en) * 2003-03-28 2006-01-04 ALTANA Pharma AG Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
EP1504756A1 (en) * 2003-08-06 2005-02-09 Kyowa Hakko Kogyo Co., Ltd Medicament compositions comprising a heterocyclic compound and an anticholinergic
RU2440813C2 (ru) 2004-02-06 2012-01-27 Меда Фарма Гмбх Унд Ко.Кг Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей
CN1913882A (zh) * 2004-02-06 2007-02-14 Meda制药有限及两合公司 用抗胆碱能药单独或联合抗组胺药、磷酸二酯酶4抑制剂或皮质类固醇来治疗鼻炎
RU2437658C2 (ru) * 2004-02-06 2011-12-27 Меда Фарма Гмбх Унд Ко.Кг Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей
WO2005102344A1 (ja) * 2004-04-27 2005-11-03 Kyowa Hakko Kogyo Co., Ltd. 医薬組成物
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
PL1863476T3 (pl) 2005-03-16 2016-07-29 Meda Pharma Gmbh & Co Kg Skojarzenie środków antycholinergicznych i antagonistów receptora leukotrienowego do leczenia chorób układu oddechowego
SI1881980T1 (sl) * 2005-05-02 2012-12-31 Boehringer Ingelheim International Gmbh Nove kristalinične oblike tiotropijevega bromida
GB0521563D0 (en) 2005-10-21 2005-11-30 Glaxo Group Ltd Novel compounds
PT1971369E (pt) 2005-12-21 2009-10-20 Meda Pharma Gmbh & Co Kg Combinação de r,r-glicopirrolato, rolipram e budesonida para o tratamento de doenças inflamatórias
SI2046787T1 (sl) 2006-08-01 2011-07-29 Glaxo Group Ltd Pirazolo(3,4-b)piridinske spojine in njihova uporaba kot PDE4 inhibitorji
WO2008127975A2 (en) * 2007-04-11 2008-10-23 Alcon Research, Ltd. Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
KR20110100679A (ko) 2009-01-13 2011-09-14 글락소 그룹 리미티드 Syk 키나아제의 억제제로서 피리미딘카르복사미드 유도체
JP5721722B2 (ja) * 2009-10-01 2015-05-20 アルコン リサーチ, リミテッド オロパタジン組成物およびその使用
WO2012025473A1 (en) 2010-08-24 2012-03-01 Glaxo Group Limited Cc.chemokine receptor 4 antagonists
WO2012025474A1 (en) 2010-08-24 2012-03-01 Glaxo Group Limited Indazole compounds
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN105121439A (zh) 2013-02-19 2015-12-02 辉瑞公司 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
KR102061952B1 (ko) 2014-08-06 2020-01-02 화이자 인코포레이티드 이미다조피리다진 화합물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000198734A (ja) * 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
BR0107964A (pt) * 2000-01-31 2002-10-29 Pfizer Prod Inc Derivados de nicotinamida benzofundida com heterociclica úteis como inibidores seletivos de isozimas pde4
WO2001070746A1 (en) * 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
AR029984A1 (es) * 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
DE10110772A1 (de) * 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
US20020137764A1 (en) * 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
UA75626C2 (en) * 2000-12-28 2006-05-15 Almirall Prodesfarma Ag Quinuclidine derivatives and medicinal compositions containing the same

Also Published As

Publication number Publication date
RU2004105865A (ru) 2005-02-20
PL368585A1 (en) 2005-04-04
CA2455520A1 (en) 2003-02-13
BR0211450A (pt) 2004-07-20
JP2004538302A (ja) 2004-12-24
EP1411914A2 (en) 2004-04-28
IL160017A0 (en) 2004-06-20
WO2003011274A3 (en) 2003-09-18
HUP0401614A2 (hu) 2004-11-29
KR20040029384A (ko) 2004-04-06
WO2003011274A2 (en) 2003-02-13
MXPA04000793A (es) 2004-05-21
ZA200400410B (en) 2004-10-13
CO5550426A2 (es) 2005-08-31
AR034900A1 (es) 2004-03-24
CN1551763A (zh) 2004-12-01
US20040180918A1 (en) 2004-09-16
GB0118373D0 (en) 2001-09-19

Similar Documents

Publication Publication Date Title
NO20040353L (no) Ny terapeutsk metode
IS7016A (is) Ný 4-anilínókínólín-3-karboxamíð
NO20035156D0 (no) Fremgangsmåter for brönnbehandling
NO20035121D0 (no) Ny anvendelse
NO20033205L (no) Terapeutiske kromanforbindelser
NO20014597D0 (no) Fremgangsmåte
DE10197149T1 (de) Anti-Zusetz-Behandlungen
NO20043664L (no) Ny fremgangsmate
NO20033919D0 (no) Ny anvendelse
DE60226093D1 (de) Urmedium-Reinigungsmethode
DE60208612D1 (de) Herzschrittmacher
FI20011252A0 (fi) Rakennusmenetelmä
SE0104471D0 (sv) New method
DE60229385D1 (de) Herzschrittmacher
SE0201055D0 (sv) New method
SE0104227D0 (sv) New method
SE0103416D0 (sv) New method
SE0103573D0 (sv) New method
SE0103357D0 (sv) New method
DOP2001000312A (es) Metodo
SE0100899D0 (sv) Method
SE0102004L (sv) Indiviva-metoden
SE0101479D0 (sv) Method
SE0100900D0 (sv) Method
FI20012580A0 (fi) Symmetrinen salausmenetelmä

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application